Table 1.
Clopidogrel | Prasugrel | Ticagrelor | |
---|---|---|---|
Binding | Irreversible | Irreversible | Reversible |
Onset of action | 2–6 h | 30 min | 30 min |
Half-life of active metabolite | 30–60 min | 30–60 min (distribution) 2–15 h (elimination) |
7–9 h |
Duration of effect | 3–10 days | 7–10 days | 3–5 days |
Frequency of administration | Once daily | Once daily | Twice daily |
Discontinuation prior to non-acute surgery | At least 5 days | At least 7 days | At least 3 days |
N/A = not applicable. In patients with ACS previously exposed to clopidogrel, switching to ticagrelor is recommended early after hospital admission at a loading dose of 180 mg irrespective of timing and loading dose of clopidogrel, unless contraindicated (IB). All other switching between P2Y12 inhibitors may be considered in cases of side effects/intolerance (IIb-C) [3].